Minjuvi 200 mg
As listed in the register: Minjuvi 200 mg, poudre pour solution à diluer pour perfusion
200 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Tafasitamabum
- Made by
- Incyte Biosciences International Sàrl
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- lymphome diffus à grandes cellules B (DLBCL), lymphome folliculaire
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Incyte Biosciences International Sàrl |
|---|---|
| Active substance | Tafasitamabum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg |
| Classification | L01FX12 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Minjuvi 200 mg, poudre pour solution à diluer pour perfusion |
| Packs | 1 Durchstechflasche(n) |
| Zulassungsnummer | 68083 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.